Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 19Esophageal Squamous Cell Carcinoma 3Recurrence 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2Pancreatic cancer, adult 1Pancreatic Adenocarcinoma 1Pan-tumor 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Locally Advanced Gastric Adenocarcinoma 1Immunotherapy Gastrict Cancer 1Cholangiocarcinoma 1Chemotherapy Effect 1

Interventions

Gemcitabine 3Radiotherapy, Intensity-Modulated 2Albumin-Bound Paclitaxel 2Taxes 1S 1 (combination) 1Radiotherapy 1Panitumumab 1Optical Imaging 1Irinotecan 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Adenocarcinoma × S 1 (combination) × Clear all
NCT06789679 2025-01-30

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
128 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡